Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations January 13, 2022 by Businesswire [#item_full_content] Related Spread the word
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish